Avita Medical (NASDAQ:RCEL) Stock Lifted to “Buy” by Wall Street Zen

Wall Street Zen upgraded shares of Avita Medical (NASDAQ:RCEL – Free Report) from a hold rating to a buy rating in a research report released on Saturday,Wall Street Zen reports.

A number of other equities analysts have also commented on RCEL. TD Cowen raised their price objective on shares of Avita Medical from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday. BTIG Research upped their target price on shares of Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Lake Street Capital increased their target price on shares of Avita Medical from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.60.

View Our Latest Report on Avita Medical

Avita Medical Price Performance

NASDAQ:RCEL traded down $0.57 on Friday, reaching $15.63. 497,276 shares of the company’s stock were exchanged, compared to its average volume of 575,372. The stock has a fifty day simple moving average of $13.40 and a 200-day simple moving average of $7.16. Avita Medical has a 52 week low of $3.22 and a 52 week high of $18.43. The firm has a market cap of $491.09 million, a price-to-earnings ratio of -13.25 and a beta of 2.03.

Avita Medical (NASDAQ:RCEL – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. The business had revenue of $26.11 million for the quarter, compared to analysts’ expectations of $22.35 million. As a group, sell-side analysts predict that Avita Medical will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Avita Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Harpswell Capital Advisors LLC bought a new stake in shares of Avita Medical during the 3rd quarter worth $150,000. China Universal Asset Management Co. Ltd. increased its stake in Avita Medical by 28.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock valued at $191,000 after acquiring an additional 3,500 shares during the last quarter. Quantinno Capital Management LP purchased a new stake in Avita Medical during the first quarter valued at about $83,000. Squarepoint Ops LLC purchased a new stake in Avita Medical during the second quarter valued at about $95,000. Finally, Ieq Capital LLC purchased a new stake in Avita Medical during the second quarter valued at about $134,000. Hedge funds and other institutional investors own 27.66% of the company’s stock.

About Avita Medical

(Get Free Report)

AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.

See Also

Analyst Recommendations for Avita Medical (NASDAQ:RCEL)

Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.